ARWR Initiated Coverage by Citigroup -- Price Target Announced a

Arrowhead Pharmaceuticals ARWR Analyst Rating Update On October 3, 2023, Arrowhead Pharmaceuticals (ARWR) received a new "Buy" rating from Citigroup analyst Eric Joseph, who has set a price target of $108.00 for the stock. GF Value™ verdict: $52.25 vs Current Price $86.57 = 65.7% overvalued GF Score™: 49/100, indicating a below-average performance Insider activity shows significant selling, with $1,186,600 in insider sell value over the past three months. What's Behind the Analyst Rating? The recent "Buy" rating from Citigroup marks a positive shift in sentiment for Arrowhead Pharmaceuticals, which has been under scrutiny in the biotechnology sector. This rating follows a series of favorable assessments from other analysts, including HC Wainwright & Co. and B. Riley Securities, who have consistently maintained or raised their price targets for the stock. The cumulative analyst outlook suggests confidence in Arrowhead's potential to deliver innovative RNAi therapies targeting various diseases. Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on developing medicines for diseases associated with genetic abnormalities or protein overproduction. With a market capitalization of approximately $12.2 billion, the company operates within the healthcare sector, specifically in the biotechnology industry. Its portfolio includes potential drugs targeting cardiometabolic, neuromuscular, pulmonary, and liver diseases, among others. Is ARWR Overvalued or Undervalued? According to GuruFocus, the GF Value™ for Arrowhead Pharmaceuticals is $52.25, which indicates that the stock is currently trading at a significant premium, approximately 65.7% overvalued based on its intrinsic value. This overvaluation is concerning, especially considering the company's unprofitability and negative cash flow, which makes traditional earnings-based valuation metrics like P/E less applicable. The trailing twelve months (TTM) P/E ratio is not available due to negative earnings, and the forward P/E stands at an astronomical 2310.37, further complicating the valuation picture. Investors should be cautious, as the historical median price-to-sales (P/S) ratio of around 22.1x suggests that the current valuation may not be sustainable. For more insights on the intrinsic value of ARWR, visit the GF Value™ page. What Does ARWR's GF Score™ Tell Us? The GF Score™ is a comprehensive measure that evaluates a company's financial strength, profitability, growth, valuation, and momentum. Arrowhead's GF Score™ of 49/100 indicates that the company is performing below average in these areas. Its strongest sub-rank is in valuation, where it ranks 3/10, while its weakest sub-ranks are in growth (1/10) and profitability (2/10), highlighting significant challenges in these critical areas. Metric Rating GF Score™ 49 Financial Strength 4/10 Profitability 2/10 Growth 1/10 Valuation 3/10 Momentum 6/10 Overall, Arrowhead's financial profile reveals significant weaknesses, particularly in growth and profitability, which could hinder its long-term performance. For a deeper look at ARWR's financial metrics, check the ARWR stock page. What Are Gurus and Insiders Doing with ARWR? Currently, six gurus hold positions in Arrowhead Pharmaceuticals, with three adding to their stakes and four trimming their holdings in recent quarters. This mixed activity reflects a cautious sentiment among institutional investors. Additionally, insider activity has been predominantly negative, with $1,186,600 in insider selling over the past three months, which may signal a lack of confidence from company insiders. What This Means for Investors Given the significant overvaluation indicated by the GF Value™ and the concerning financial metrics reflected in the GF Score™, investors should approach Arrowhead Pharmaceuticals with caution. The combination of high insider selling and a low growth rank suggests that while analysts may be optimistic, the underlying financial health of the company raises red flags. For more detailed analysis, visit the ARWR stock page. Frequently Asked Questions What is ARWR's GF Score™? ARWR's GF Score™ is 49/100, indicating below-average performance in key financial metrics. Is ARWR overvalued or undervalued? ARWR is currently considered significantly overvalued, trading at approximately 65.7% above its GF Value™ of $52.25. What do analysts recommend for ARWR? Analysts have a generally positive outlook, with a "Buy" rating and price targets ranging from $100.00 to $120.00.